The Market LogEnter at least 2 characters. Company and ticker searches are not case-sensitive.

Transaction #33823 · Form 4 · 0001683168-26-007901

AETHLON MEDICAL INC · Stock award · Common Stock

AETHLON MEDICAL INC · Transacted October 8, 2026 · Filed October 15, 2026

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for AETHLON MEDICAL INC records a stock award involving Common Stock on October 8, 2026. The reported quantity was 42,000. The filing date is October 15, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0000882291
Security type
Non-derivative
Acquisition type
Stock award · Code A
Quantity acquired
42,000
Reported price
0
Reference value
0
Currency
Currency not specified
Ownership
Direct
Holdings after transaction
42,057
Ownership description
Not reported
SEC acceptance time
Oct 15, 2026, 4:08 PM EDT
10b5-1 indication
Not indicated

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

AEMD · Nasdaq · linked security

The linked listing is identified separately from other current company listings.

Filing footnotes & remarks

F1
Represents a grant of 42,000 restricted stock units ("RSUs") pursuant to the Issuer's 2020 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest over the one-year period following October 8, 2026, subject to the Reporting Person's continued service through the applicable vesting dates. Notwithstanding the foregoing, the RSUs will become fully vested upon the closing of the Issuer's proposed merger with North Immunology, Inc.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.